GLP1 Protocol
checklistEvidence review

BPC-157 Protocol: The Sequence the Research Followed

The word protocol does two different jobs, one in a methods section and one on a forum. Only one of them has published work standing behind it.

A BPC-157 protocol, in the sense the published research uses that word, is an experimental design: which animal, which injury model, which route, which measurement, and in what order. That is a different object from the numbered schedules that circulate under the same name. The distinction is not pedantic. Almost everything published on this peptide describes work in rats and in cell culture, and a design written for a severed rat tendon does not become a plan for a person just by changing the units.

Where the order actually gets placed

Ascension Peptides, BPC-157

US-based, with no batch certificate published for this product. Enter the code on the payment step and either option halves before you confirm.

CodePEPTIDEDECK50% off
BPC-157 · 10 mg$49.00$24.50Get BPC-157 →
Wolverine Stack · with TB-500, 20 mg Best value$90.00$45.00Get the stack →

The Wolverine Stack is BPC-157 10 mg combined with TB-500 10 mg in one vial, so its per-mg figure spans both compounds. Quantity tiers take 3%, 5% or 10% off the list price; free shipping starts at $250.

What a BPC-157 protocol specifies in a published study

Open the methods section of one of the tendon or gut papers and the same slots appear every time, in roughly the same order.

It names the species, and often the strain. A rat model and a mouse model are not interchangeable, and the efficacy work on this peptide leans heavily on rats.

It names the injury. This literature uses transected or crushed tendon, damaged muscle, chemically induced gastric lesions, and surgically created bowel injuries. The injury is made by the experimenters at a known minute on a known day. That is the single largest difference between a study and anything happening in a human body, where the damage arrived on its own schedule and nobody recorded the moment.

It names the route. Injection into the abdominal cavity, injection into muscle, and delivery in drinking water all appear across the rat work. These are not equivalent exposures and the papers do not treat them as such.

It names the amount per kilogram of body weight, which is a unit that exists only because the animals were weighed that morning.

It names the timing relative to the injury: how soon after, how often, for how many days.

And it names the endpoint, which is what the whole design points at. Endpoints here are mechanical pull tests on a healed tendon, histology scores read under a microscope, measured lesion area, or markers counted in tissue. In most of these designs the tissue is collected after the animal is euthanised. That fact alone explains why the sequence cannot simply be copied: the final step is not available outside a laboratory.

Protocol elementWhat the animal studies specifyWhether it carries over
SpeciesRat in most efficacy work, cell culture for mechanismNo, this is the thing being studied
InjuryCreated by the researcher at a known timeNo, human injuries are not scheduled
RouteAbdominal cavity, muscle, or drinking waterNot established for people
AmountPer kilogram of animal body weightNo validated human conversion published
TimingFixed relative to the moment of injuryOnly if that moment is known and recorded
EndpointTissue collected and measured directlyNo, tissue is not retrievable from a living person

The order a rat tendon study actually runs in

The sequence is worth walking through, because the shape of it is what gets lost when a protocol is retold as a list of numbers.

First, the animals are acclimatised and weighed. Weight is not a formality here, it is the denominator for everything that follows.

Second, the groups are assigned. There is a treated group and at least one control group, and in the better designs the person scoring the tissue at the end does not know which is which.

Third, the injury is created under anaesthesia, at a recorded time.

Fourth, administration begins, at a fixed interval after that recorded time. In much of this work the first administration comes very soon after the injury, which is a condition almost nobody outside a laboratory can reproduce.

Fifth, the animals are maintained and observed for a defined number of days.

Sixth, the tissue is collected and measured. This is where the result is generated. Everything before it was setup.

Seventh, the numbers from the treated group are compared against the control group, and the difference between them is the finding. Not the treated group on its own. The comparison is the result, which is why a protocol without a control group produces nothing at all.

Why the human sequence cannot be the same sequence

Three of those seven steps are unavailable outside animal work. You cannot schedule the injury. You cannot euthanise the subject to read the tissue. And you cannot run yourself as both the treated group and the control at once, because you only get one course of healing per injury.

That last point is the one most often missed. A person following a schedule and feeling better afterwards has produced a treated group with no control. Tendon, muscle and gut tissue all recover to some degree on their own, over weeks to months, and no personal record can separate that recovery from anything else. The rat studies bother with control groups precisely because the untreated animals also improve.

Where the registered human trials sit in the sequence

Human trials on BPC-157 do exist and are registered, which makes the flat claim that there are none inaccurate. Two are citable. NCT07803250 is a Phase 1 study with a planned enrolment of 30 participants looking at recovery after rotator cuff repair, listed as not yet recruiting. NCT02637284 is a Phase 1 study of 42 participants covering safety and pharmacokinetics, with status listed as unknown.

None of these has published efficacy results. That is the honest position, and it is a position in the middle: registered human work exists, and it has not reported yet. Both halves are true at the same time.

What those trials will do, when they report, is supply the steps that animal work structurally cannot. A defined injury with a known date, a control arm, blinded assessment, and endpoints that can be measured in a living person, such as return to activity or imaging. That is the sequence that would make the word protocol mean something for a human reader.

What a circulating BPC-157 protocol is actually built from

Trace a forum schedule back and it usually resolves into three ingredients. A number lifted from a rat study and converted by body weight, using a conversion the original authors never endorsed. A duration borrowed from the culture of anabolic cycling, which is a convention rather than a finding. And a route chosen for convenience.

None of those three has a published human study behind it. That does not make every number dangerous by itself, but it does mean the schedule has the appearance of a protocol without the thing that makes a protocol a protocol, which is a design that produces a measurable answer.

There is also a regulatory step that sits before all of this and gets skipped. BPC-157 holds no marketing authorisation from the FDA, the EMA or the MHRA. It is sold as a research chemical. A research chemical has no approved labelling, which means there is no authority anywhere in the chain that has reviewed a schedule and signed off on it.

Reading a protocol you found, in order

If you are going to read one anyway, read it in this sequence and the weak joints show up quickly.

Ask what organism the underlying evidence came from. If the source is a rat study, everything downstream is an extrapolation, and the extrapolation should be stated rather than hidden.

Ask whether the source is named at all. A protocol that cites nothing has no failure point you can inspect.

Ask what the control was. If there is no comparison group anywhere in the chain, there is no finding, only a description of what happened.

Ask what was measured, and whether it is something a person can actually observe. Tissue histology is not.

Ask who wrote it and what they sell. This is not a character question, it is a design question, because a protocol written by a vendor has an endpoint of its own.

Related reading on this compound: what BPC-157 actually is, whether cycling applies here, the benefit claims graded by organism.

Questions about a BPC-157 protocol

Is there an official BPC-157 protocol anywhere?expand_more
No. There is no approved labelling, because there is no marketing authorisation from the FDA, the EMA or the MHRA. Study protocols exist inside published papers and inside the registered trials, but those are experimental designs, not instructions.
Do the rat studies give a schedule that could be adapted?expand_more
They give schedules built around an injury created at a known time in an animal that gets weighed and then examined internally. The timing anchor and the measurement step both disappear outside that setting, so what remains is a fragment rather than an adaptable design.
Why do published protocols vary so much between papers?expand_more
Because they are answering different questions in different tissues. A gut lesion study and a tendon transection study need different injuries, different timings and different endpoints. Variation between designs is normal in animal research and is not a sign that any one of them is the correct human answer.
Do the registered trials publish their protocols?expand_more
Trial registrations list design features such as phase, planned enrolment, condition and outcome measures. For the three citable BPC-157 entries, that registration information exists, but efficacy results have not been published, so there is nothing yet to read as a result.
What is missing from every consumer protocol?expand_more
A control group, a blinded assessor, and a measurable endpoint. Those three are what convert a sequence of actions into evidence. Without them a schedule can be followed precisely and still produce no information.